GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (NYSE:IQV) » Definitions » Gross Margin %

IQV (IQVIA Holdings) Gross Margin % : 34.77% (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is IQVIA Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. IQVIA Holdings's Gross Profit for the three months ended in Jun. 2024 was $1,326 Mil. IQVIA Holdings's Revenue for the three months ended in Jun. 2024 was $3,814 Mil. Therefore, IQVIA Holdings's Gross Margin % for the quarter that ended in Jun. 2024 was 34.77%.


The historical rank and industry rank for IQVIA Holdings's Gross Margin % or its related term are showing as below:

IQV' s Gross Margin % Range Over the Past 10 Years
Min: 27.49   Med: 34.07   Max: 35.21
Current: 35.1


During the past 13 years, the highest Gross Margin % of IQVIA Holdings was 35.21%. The lowest was 27.49%. And the median was 34.07%.

IQV's Gross Margin % is ranked worse than
67.49% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: 47.88 vs IQV: 35.10

IQVIA Holdings had a gross margin of 34.77% for the quarter that ended in Jun. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for IQVIA Holdings was 0.00% per year.


IQVIA Holdings Gross Margin % Historical Data

The historical data trend for IQVIA Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings Gross Margin % Chart

IQVIA Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.16 33.97 33.45 34.89 34.96

IQVIA Holdings Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.47 35.06 35.94 34.60 34.77

Competitive Comparison of IQVIA Holdings's Gross Margin %

For the Diagnostics & Research subindustry, IQVIA Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's Gross Margin % falls into.



IQVIA Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

IQVIA Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=5239 / 14984
=(Revenue - Cost of Goods Sold) / Revenue
=(14984 - 9745) / 14984
=34.96 %

IQVIA Holdings's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=1326 / 3814
=(Revenue - Cost of Goods Sold) / Revenue
=(3814 - 2488) / 3814
=34.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


IQVIA Holdings  (NYSE:IQV) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

IQVIA Holdings had a gross margin of 34.77% for the quarter that ended in Jun. 2024 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


IQVIA Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


IQVIA Holdings Business Description

Traded in Other Exchanges
Address
2400 Ellis Road, Durham, NC, USA, 27703
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Executives
Eric Sherbet officer: See Remarks 100 IMS DRIVE, PARSIPPANY NJ 07054-4235
Ari Bousbib director, officer: Chairman, CEO & Pres UNITED TECHNOLOGIES CORP, ONE FINANCIAL PLAZA, HARTFORD CT 06101
W Richard Staub officer: See Remarks
Kevin C Knightly officer: Pres Info & Tech Solutions 1499 POST ROAD, FAIRFIELD CT 06824
Panagos Constantinos officer: See Remarks 4280 EMPEROR BLVD, DURHAM NC 27703
Keriann Cherofsky officer: See Remarks 4280 EMPEROR BLVD, DURHAM NC 27703
Sheila A Stamps director C/O CIT GROUP, 1 CIT DRIVE, ATTN: GENERAL COUNSEL, LIVINGSTON NJ 07039
Morris Leslie Wims director 4280 EMPEROR BLVD, DURHAM NC 27703
John Connaughton director, 10 percent owner BAIN CAPITAL PARTNERS LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Ronald E Bruehlman officer: See Remarks C/O IQVIA HOLDINGS, INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
Ronald A Rittenmeyer director 5400 LEGACY DRIVE, PLANO TX 75024
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Michael J Evanisko director BRAUN CONSULTING, 20 W KINZIE STREET SUITE 1600, CHICAGO IL 60610
Michael R Mcdonnell officer: Chief Financial Officer C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
John M. Leonard director C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139